Effect of ESWT Applied After Botulinum Toxin Injection on Ankle Spasticity in Stroke Patients.

Launched by SAGLIK BILIMLERI UNIVERSITESI · Nov 6, 2023

Keywords

ClinConnect Summary

In this double-blind randomized placebo-controlled trial, 45 patient (aged 18-75) diagnosed as stroke with appropriate criteria will be included.

Patients who meet the inclusion criteria for the study will be seperated into three groups with the randomizer.org randomization program.

Group I: A single session of rESWT will be applied on the same day after BTX-A injection.

Group II: A total of 2 sessions of rESWT will be applied on the same day after BTX-A injection and on the 7th day after BTX-A injection.

Group III: A single session of placebo rESWT will be applied after BTX-A injection...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Having an ischemic or hemorrhagic stroke, in subacute or chronic phase,
• • Patients with ankle plantar flexor spasticity MAS score \> 1 and patients who received BTX-A injection due to spasticity
• • Stroke history of at least 3 months
• Exclusion Criteria:
• • History of neuromuscular disease
• • Compared to the unaffected side; More than 50% reduction in dorsiflexion range of motion of the affected side
• • Dynamic ankle contracture
• • Affected side lower extremity surgery in the last 12 months
• • Having Botox or phenol application to the affected gastrocnemius in the last 3 months
• • Change in the dose of antispastic medication used in the last 3 months
• • Infection/wound in the affected lower extremity
• • Contraindications for ESWT (pregnancy, cancer, bleeding disorders, inflammatory disease, pacemakers or other electronic implants).
• • Significant muscle atrophy or fibrosis of the target muscle (Heckmatt scale III and IV)